Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503451 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
A Phase 1 study of Neoplasms and Non-Hodgkin Lymphoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT00503451: Completed Phase 1 study of Neoplasms and Non-Hodgkin Lymphoma, sponsored by Novartis Pharmaceuticals.
NCT00503451 is a Phase 1 study of Neoplasms and Non-Hodgkin Lymphoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00503451, a Phase 1 study of Neoplasms and Non-Hodgkin Lymphoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors. The extension phase of the study will evaluate the safety and efficacy of LBH589 in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG LBH589
Study Locations (2)
Nevada
- Nevada Cancer Institute - Las Vegas
Other
- Novartis Investigative Site - Rotterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-09 |
| Phase | Phase 1 |
What the finished NCT00503451 record still lists
NCT00503451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which LBH589 is the first listed.
NCT00503451 reports a single indexed study location in Nevada, Other.
Frequently Asked Questions
What is clinical trial NCT00503451 about?
NCT00503451 is a clinical study titled "A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors". The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors. The extension phase of the study will evaluate the safety and efficacy of LBH589 in patients with advanced solid tumo...
What is the current status of trial NCT00503451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2007-09.
What conditions does trial NCT00503451 study?
This clinical trial studies the following conditions: Neoplasms, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT00503451?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00503451?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00503451 being conducted?
This trial has 2 study locations across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00503451's enrollment target sits among peer trials
14 152nd of 158 higher than 7 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia